

RECEIVED  
CENTRAL FAX CENTER

DEC 07 2006

U.S. Appl. No. 09/529,053

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the Application:

1-25. (Canceled)

26-33. (Canceled)


34. (Currently amended) A method of treating a patient suffering from a viral infection comprising administering to said patient ~~[[a]]~~ a therapeutically effective amount of a leflunomide product and ~~[[b]]~~ administering to said patient a pyrimidine compound without antiviral activity in an amount effective to enhance serum levels of uridine, cytidine or thymidine.

35. (Previously presented) The method of claim 34 wherein the leflunomide product is N-(4-trifluoromethylphenyl)-5-methylisoxazol-4-carboxamide (HWA 486).

36. (Previously presented) The method of claim 34 wherein the leflunomide product is N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxycrotonamide (A771726).

37. (Previously presented) The method of claim 34 wherein the leflunomide product is an amide of a malononitrile.

38. (Currently amended) The method of claim 34 or 41 wherein the leflunomide product is a compound of formula:



wherein

R<sup>1</sup> denotes  
a) methyl,

U.S. Appl. No. 09/529,053

- b) (C<sub>3</sub>-C<sub>6</sub>)-cycloalkyl,
- c) (C<sub>2</sub>-C<sub>6</sub>)-alkyl, having at least 1 triple or double bond between the carbon atoms,

R<sup>2</sup> denotes

- a) —CF<sub>3</sub> or
- b) —CN,

R<sup>3</sup> denotes

- a) (C<sub>1</sub>-C<sub>4</sub>)-alkyl or
- b) hydrogen atom,

X denotes

- a) —CH—group or
- b) nitrogen atom,

the compound being present as such or in the form of a physiologically tolerable salt.

39. (Previously presented) The method of claim 34, 35, 36 or 37 wherein the virus is a herpesvirus.

40. (Previously presented) The method of claim 34, 35, 36 or 37 wherein the virus is selected from the group consisting of paramyxoviruses, picornaviruses, hepatitis viruses, CMV, HSV, measles virus, rhinoviruses, hepatitis B and hepatitis C.


41. (Previously presented) The method of claim 34 wherein the pyrimidine is uridine, orotic acid or orotidine.

42. (Previously presented) The method of claim 37 wherein the pyrimidine is uridine, orotic acid or orotidine.

43-44. (Canceled)

45. (New) The method of claim 34 or 41 wherein the leflunomide product is a compound of formula I or II:

U.S. Appl. No. 09/529,053



wherein in formula I or II

R<sup>1</sup> denotes

- a) methyl,
- b) (C<sub>3</sub>-C<sub>6</sub>)-cycloalkyl,
- c) (C<sub>2</sub>-C<sub>6</sub>)-alkyl, having at least 1 triple or double bond between the carbon atoms,

R<sup>2</sup> denotes

- a) —CF<sub>3</sub> or
- b) —CN,

R<sup>3</sup> denotes

- a) (C<sub>1</sub>-C<sub>4</sub>)-alkyl or
- b) hydrogen atom, and

X denotes

- a) —CH—group or
- b) nitrogen atom;

the compound being present as such or in the form of a physiologically tolerable salt.

46 45. (New) A method of treating a patient suffering from a viral infection comprising administering to said patient (a) a therapeutically effective amount of a leflunomide product and (b) a pyrimidine compound without antiviral activity.